UroGen Pharma Ltd. Net Change in Cash
UroGen Pharma Ltd. (URGN) reported Net Change in Cash of -$31.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-05
- UroGen Pharma Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$800.00K.
- UroGen Pharma Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$67.95M, a 286.48% decline year-over-year.
- UroGen Pharma Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $36.44M.
- UroGen Pharma Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$18.87M, a 131.27% decline year-over-year.
- UroGen Pharma Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$60.97M, a 178.93% decline from fiscal 2024.
- UroGen Pharma Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $77.24M, a 95.04% increase from fiscal 2023.
- UroGen Pharma Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $39.60M, a 272.37% increase from fiscal 2022.
- UroGen Pharma Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $10.63M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$31.63M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$800.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$60.97M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | -$81.68M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$79.08M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | -$67.95M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $77.24M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $30.17M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $124.97M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $36.44M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $39.60M 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $63.90M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | -$35.28M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$18.87M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $10.63M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | -$16.09M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $35.91M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $60.34M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$8.50M 10-K · filed 2023-03-24 | |||
| 2021-09-30 | $2.47M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $10.46M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$12.37M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $3.88M 10-K · filed 2022-03-21 | |||
| 2020-09-30 | -$24.42M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$12.64M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | -$22.52M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$51.36M 10-K · filed 2021-03-18 | |||
| 2019-09-30 | -$34.90M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$10.84M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $145.53M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $64.37M 10-K · filed 2020-03-02 | |||
| 2018-09-30 | $72.48M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $82.11M 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | $90.46M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $15.74M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $3.46M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |